High-Risk Melanoma
Speaker discusses predictive power of Merlin test for low-, high-risk melanoma
ORLANDO — A presentation at the American Society for Dermatologic Surgery Annual Meeting detailed new data that showcased the validity of the Merlin test in identifying sentinel lymph node biopsy status in high-risk patients with melanoma.
Vibostolimab, pembrolizumab coformulation trial discontinued for resected high-risk melanoma
Merck has discontinued the vibostolimab and pembrolizumab coformulation arm of its phase 3 trial for the adjuvant treatment of patients with resected high-risk melanoma, the company announced in a press release.
mRNA combination therapy produces positive results in patients with high-risk melanoma
Adjuvant treatment with messenger RNA in combination with Keytruda produced meaningful improvement in patients with resected high-risk melanoma, according to findings from a phase 2b study.
Vaccine-immunotherapy combination extends RFS in high-risk melanoma
The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.
FDA grants priority review to Keytruda for stage II resected high-risk melanoma
The FDA granted priority review to pembrolizumab for adjuvant treatment of certain patients with high-risk melanoma.